Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCIDA Treatment: LX201 for Corneal Graft Rejection
NCT00447642Phase 3Terminated
- Sponsor
- Lux Biosciences, Inc.
- Start
- Apr 2007
- Primary completion
- Aug 2008
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of cyclosporine in corneal graft rejection (CGR), sponsored by Lux Biosciences, Inc.. Started Apr 2007; status: terminated.
02
Drugs
cyclosporine
03
Conditions
corneal graft rejection (CGR)
Beyond the preview
Go deeper on NCT00447642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447642.